肿瘤细胞减灭术联合腹腔热灌注化疗(CRS/HIPEC)治疗结直肠癌腹膜转移的现状和进展  

The status and progress of tumor cell reduction combined with intraperitoneal hyperthermic perfusion chemotherapy(CRS/HIPEC)in the treatment of peritoneal metastasis of colorectal cancer

作　　者：孙立峰[1] 丁克峰[1] Sun Lifeng;Ding Kefeng(Department of Colorectal Surgery,the Second Affiliated Hospital of Zhejiang University Medical College,Cancer Diagnosis and Treatment Center,Zhejiang University,Hangzhou 310009,China)

机构地区：[1]浙江大学医学院附属第二医院大肠外科暨浙江大学大肠癌诊治中心,杭州310009

出　　处：《中华结直肠疾病电子杂志》2020年第2期127-130,共4页Chinese Journal of Colorectal Diseases(Electronic Edition)

摘　　要：腹膜是结直肠癌转移的好发部位。结直肠癌发生腹膜转移长期以来被认为预后很差,主要采用姑息性手段治疗。尽管化疗及靶向治疗在结直肠癌治疗上有很大进展,但对于腹膜转移的结直肠癌疗效并不理想。最近越来越多的证据表明,肿瘤细胞减灭术(CRS)联合腹腔内热灌注化疗(HIPEC)的治疗方法能给这部分患者带来较大的生存获益。本文综述了结直肠癌腹膜转移的诊治现状和相关进展。目前认为CRS联合HIPEC对选择的结直肠癌腹膜转移患者是一种安全有效的治疗模式,但HIPEC能否预防进展期结直肠癌发生腹膜转移,还有待进一步的临床试验研究。Peritoneum is the common site of colorectal cancer metastasis and always be regarded as the type with the poorest prognosis which relies on palliative treatment.Though chemotherapy and targeted drugs have made much progress on colorectal cancer,their effect on peritoneal metastasis are not quite well.Recently,more and more evidence indicates that the combination of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy can achieve a long-term survival in selected patients with colorectal peritoneal metastasis.This review summarizes the current situation of CRS and HIPEC on different peritoneal metastasis and especially on colorectal peritoneal metastasis which indicates that the combination therapy modality is a safe and efficient way for colorectal peritoneal metastasis.

关 键 词：结直肠肿瘤 腹膜转移 肿瘤细胞减灭术 腹腔内热灌注化疗 

分 类 号：R735.3[医药卫生—肿瘤]